Goldman Sachs upgrades GE Healthcare amid stabilizing Chinese healthcare market

March 12, 2025 02:07 AM AEDT | By Investing

Google News:

Goldman Sachs upgrades GE Healthcare amid stabilizing Chinese healthcare market

Recent News

FTSE 100 today: Index flat ahead of U.S.-China talks in London; WPP CE...

Sungrow Releases the Groundbreaking PowerTitan 3.0 Energy Storage Syst...

"Aptos EXPO Memorial Stamp Rally" Goes Live in Celebration of Expo 202...

MEXC Unveils New Launchpad Featuring BTC to Kick Off BTC Trading Month

Investing.com -- Goldman Sachs raised rating on GE HealthCare Technologies Inc (NASDAQ:GEHC) to "Buy" from "Neutral” as China's healthcare market is showing signs of stabilization, with demand for medical technology and diagnostic tools expected to rebound in 2025.

Amid an ongoing policy and trade uncertainties, Goldman Sachs (NYSE:GS) said pent-up demand and government stimulus programs are helping to ease market slowdowns.

The healthcare sector in China has faced several headwinds in recent years, including government price controls on medical equipment, anti-corruption measures, and delays in stimulus programs meant to boost investment.

These challenges led multinational healthcare firms such as GE Healthcare, Philips, and Siemens (ETR:SIEGn) Healthineers to cut sales forecasts in China for 2024.

However, Goldman Sachs noted that capital investment in medical technology is beginning to recover, leading to a more positive outlook for 2025. While global companies have been reducing their focus on China, local firms are expanding into international markets.

Goldman Sachs expects companies with strong innovation and differentiated technology to benefit from the recovery. Besides upgrading GE Healthcare, the bank remains positive on Boston Scientific (NYSE:BSX) and Intuitive Surgical (NASDAQ:ISRG), both of which offer advanced medical solutions.

Meanwhile, European medical technology firms such as Siemens Healthineers and Philips are also expected to see easing pressures in China over the next 12 to 18 months. Goldman Sachs has raised its earnings forecasts for Siemens Healthineers and upgraded Carl Zeiss to "Buy," citing improving demand in China’s ophthalmology sector.

However, some companies remain under pressure. The report warned that price controls on diagnostic reagents could continue to hurt profitability. Danaher (NYSE:DHR) has already increased its estimated losses from these regulations to $150 million in 2025, with further risks in 2026 as Chinese competitors gain market share.

In the life sciences sector, Goldman Sachs sees opportunities for companies such as Agilent (NYSE:A) and Thermo Fisher (NYSE:TMO) to benefit from government stimulus for research and diagnostics. Companies like Waters (NYSE:WAT) and Bruker (NASDAQ:BRKR) could also gain in the longer term as funding expands beyond basic applications like food and water testing.

Despite rising competition from Chinese firms, Goldman Sachs believes foreign players still hold an advantage in high-end medical technology, such as electron microscopes and mass spectrometry equipment.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.